Novo Nordisk's NASH drug is WORSE than placebo --
Post# of 148183
Quote:
In the study of 71 NASH patients with compensated cirrhosis (the F4 stage of the disease), only 10.6% of those who received a weekly 2.4 mg dose of semaglutide saw an improvemen t in liver fibrosis coinciding with no worsening of NASH. The figure for those on placebo was 29.2%.
As a secondary endpoint, 34% of patients on semaglutide saw a resolution of NASH—which means improvement in liver inflammation and liver cell ballooning—versus 20.8% on placebo.
https://www.fiercepharma.com/pharma/after-pha...-fail-nash